Top Updates Back
Noven Pharmaceuticals, Inc.
1987-01-01
Jersey
Research and Development of Prescription Pharmaceutical Products
Manufacturing of Transdermal Patches
Marketing and Sale of Prescription Pharmaceutical Products
Transdermal Drug Delivery Solutions
Research and development of prescription pharmaceutical products
Manufacturing of prescription pharmaceutical products
Marketing and sale of prescription pharmaceutical products
Commercialization of transdermal drug delivery systems
Development of transdermal delivery technology
XELSTRYM (dextroamphetamine transdermal system)
SECUADO (asenapine transdermal system)
COMBIPATCH (estradiol/norethindroneacetate transdermal system)
Methylphenidate Transdermal System CII
Estradiol Transdermal System
Miami, Florida and Jersey City, New Jersey, USA
Takeshi Masumoto
300 people
Company name
Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Hisamitsu Pharmaceutical Co., Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Parent
Noven Therapeutics, LLC
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Customer
Noven Therapeutics
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders

20 entries
DateDescription
1998-02 Launch of CombiPatch ® (estradiol/norethindrone acetate transdermal system), the first combination (two-drug) patch
1999-02 Launch of Vivelle-Dot ® (estradiol transdermal system), the world's smallest estrogen patch at the time
2003-02 Shire licenses Noven's Daytrana ® patch for ADHD
2006-02 Shire and Noven launch Daytrana ®
2007-02 Noven acquires JDS Pharmaceuticals, expanding its portfolio and sales capabilities
2009-02 Noven acquired by Hisamitsu Pharmaceuticals; public company status concludes
2010-02 Noven reacquires Daytrana
2010-02 Hisamitsu Carlsbad facility integrated with Noven operations
2011-02 Noven's Northeast operations consolidated in Empire State Building co-headquarters
2012-10 Minivelle approved by FDA
2012-12 Noven acquires Minivelle, establishes Women's Health sales team
2013-01 Noven Women's Health team launches Minivelle
2013-06 Brisdelle approved by the FDA
2013-11 Launch of Brisdelle
2015-02 Minivelle (Estradiol Transdermal System) 0.025 Mg/Day Dose Available By Prescription In U.S. Pharmacies. UPDATE: MINIVELLE has been removed from Market. ESTRADIOL TS, the authorized generic to MINIVELLE is available.
2016-06 Brisdelle (paroxetine) and Pexeva (paroxetine) acquired by Sebela Pharmaceuticals
2019-10 SECUADO (asenapine) transdermal system FDA approval
2020-03 Launch of SECUADO
2022-03 Approval of XELSTRYM
2023-06 Launch of XELSTRYM
+ Loaded when opened
✅
2026-09-21 18:06 (Model: gpt-oss-20b(99) )
↑